Biotech

Luminex Announces Commercial Launch of New Cystic Fibrosis Test

August 26, 2010

New Test Detects up to 60 Genetic Mutations
 

BioMarin Acquires ZyStor Therapeutics, Inc.

August 17, 2010

ZyStor's lead product candidate is ZC-701
 

Signum Biosciences Names Braham Shroot as Chief Executive Officer

August 05, 2010

Experienced pharmaceutical executive leads innovative biotech company
 

Radient Pharmaceuticals Enters Into a Letter of Intent to Acquire Provista Diagnostics Inc.

July 13, 2010

Diagnostic technologies will strengthen and complement Radient's core business
 

Genentech Submits Application to FDA for Trastuzumab-DM1 in Previously Treated Advanced HER2-Positive Breast Cancer

July 07, 2010

T-DM1 is the First Antibody-Drug Conjugate in Genentech's Pipeline to Be Submitted to the FDA
 

Celgene to Acquire Abraxis BioScience Inc.

June 30, 2010

Celgene to pay $2.9 billion in cash and stock
 

Spectrum Pharmaceuticals Appoints James E. Shields as Chief Commercial Officer

June 23, 2010

Company Continues Its Focus on Maximizing the Value of Its Two Marketed Anticancer Drugs
 
 

Ablexis Appoints R. Scott Greer Chairman of the Board and Richard Hoffman Chief Business Officer

June 22, 2010

Expanding Senior Management Team Supports Next-Generation Platform for Antibody Drug Discovery
 

aTyr Pharma Appoints Catharine E. Johnson As Senior Vice President of Business Development

June 14, 2010

Dr. Johnson's has extensive biotechnology industry experience
 

3M Introduces New, Innovative 3M Tegaderm High Performance Foam Adhesive Dressing

June 11, 2010

Studies demonstrating superior performance to be presented at WOCN/WCET Joint Conference
 

Centocor Ortho Biotech Inc. Acquires RespiVert Ltd.

June 01, 2010

Acquisition strengthens pulmonary focus
 

PerkinElmer Enters Into Agreement to Acquire Signature Genomic Laboratories, LLC

April 14, 2010

Acquisition brings new diagnostic services to global leader in pre-natal and newborn health screening
 
 

Fate Therapeutics Expands Stem Cell Modulator Pipeline with Acquisition of Verio Therapeutics

April 08, 2010

Fate Therapeutics forms a Canadian subsidiary
 

Dr. Thomas Hofstaetter Named President and CEO of VaxInnate

March 18, 2010

Dr. Alan Shaw Assumes New Role as Chief Scientific Officer and Chairman
 

ABRAXANE Meets Primary Endpoint in Phase 3 Trial for Advanced Non-Small Cell Lung Cancer

March 17, 2010

ABRAXANE, Carboplatin Combination Demonstrated Superiority to Taxol
 

Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech

March 09, 2010

Abbott will acquire Facet for $27 per share in cash
 

Alun Malone Joins Millennium Laboratories As New Business Development Executive

March 08, 2010

Mr. Malone brings knowledge and experience in the therapeutic drug monitoring industry
 

Genentech Announces Positive Results of Avastin Phase III Study in Women with Advanced Ovarian Cancer

February 25, 2010

First Phase III Study of an Anti-Angiogenic Therapy in Advanced Ovarian Cancer to Meet Primary Endpoint
 

FDA Approves Rituxan Plus Chemotherapy for the Most Common Type of Adult Leukemia

February 18, 2010

Approval Based on Data From Two of the Largest Trials Ever Conducted in Chronic Lymphocytic Leukemia
 

Gary J. Beeman Appointed CEO of GeneLink BioSciences, Inc.

February 18, 2010

Sharon M. Tahaney Appointed President of GeneWize Life Sciences, Inc.
 

Mipomersen Phase 3 Study in Patients with Heterozygous Familial Hypercholesterolemia Meets Primary Endpoint

February 10, 2010

28 Percent LDL-C Reduction in High-Risk Patient Population
 

Xencor Appoints Edgardo Baracchini, Ph.D., to Chief Business Officer

February 09, 2010

Mr. Baracchini brings more than 15 years of transactional experience
 

FDA Accepts Javelin Pharmaceuticals' Submission and Files New Drug Application for Dyloject(TM)

February 02, 2010

Key Milestone in the Proposed Merger of Myriad Pharmaceuticals and Javelin Pharmaceuticals
 

Ligand Completes Acquisition of Metabasis

January 28, 2010

Ligand gains a fully funded partnership with Roche
 

Spectrum Pharmaceuticals Terminates Ozarelix Development Program in Benign Prostate Hypertrophy (BPH)

January 27, 2010

Spectrum Continues Major Effort to Prioritize Product Portfolio
 
 

Biogen Idec Issues Statement on U.S. Approval of AMPYRA (dalfampridine)

January 23, 2010

New Oral Therapy Addresses Key Need for MS Community
 

Abbott Receives European Regulatory Approval for New Ovarian Cancer Diagnostic Test

January 14, 2010

Abbott announces CE Mark (Conformite Europeene) certification for the ARCHITECT human epididymis protein 4 (HE4) test
 

Latest News

Popular Topics
Acquisition Agency Animal Health Biopharmaceutical Biotech Business Clinical Management Collaboration Diagnostic Marketing & Communications Medical Device Medical Equipment Merger New Hire New Hires Personnel Pharmaceutical Pharmaceutical Products Pipeline Product Acquisition Product Launch Product Promotion Regulatory Regulatory Approval Research & Development